



February 18th, 2021
BioComo Inc.

BioComo announces that MediciNova has not been granted exclusive worldwide rights to use BC-PIV for SARS-CoV-2 vaccine from BioComo and Mie University yet

BioComo, Inc. today announced that a definitive agreement to grant MediciNova, Inc. the rights to use BC-PIV has not been reached yet, although BioComo and MediciNova, Inc. agreed to develop a new SARS-CoV-2 vaccine based on a non-binding term sheet signed on July 27, 2020.

BioComo and Mie University are continuing the development of new SARS-CoV-2 vaccines using BC-PIV.

【About BioComo Inc.】

Privately held biotech company, founded in May 2008

Head Office : 1325 Komono, Mie-gun, Mie, Japan 510-1233

Executive Member:

Masayuki Fukumura, Ph.D., Founder, CEO & CSO

Hiromu Ozaki, Board, BD

Hiroki Hideshima, Board, CFO

Mitsuhiro Fujita, Board

URL: <http://biocomo.jp/>

Category of Business: Vaccines against infectious diseases and
Immunomodulators for solid tumors

Contact: info@biocomo.jp